FDA flags concerns on Pfizer kidney cancer drug; Momenta gets Virdante tech in $56M deal; Regeneron slides on head-to-head data;

 @FierceBiotech: Novartis aiming to impress investors, academics as it presents flurry of data on its growing cancer franchise. Article | Follow@FierceBiotech

 @RyanMFierce: Profile on former Icahn biotech lieutenant Alex Denner via Bloomberg--Still not many details on his hedge fund. Item | Follow @RyanMFierce

 @JohnCFierce: U.K. offering $280M catalyst fund, patient data access for biotech R&D. Story | Follow @JohnCFierce

 @MarkHFierce: The Aussies have found a gene that stops skin cancer. Treatments could follow in 5 years? We'll see. More | Follow@MarkHFierce

> Two days ahead of an advisory committee meeting, FDA staffers raised concerns that Pfizer's kidney cancer drug axitinib may help only a small group of patients and may not help much in spurring progression-free survival rates. Story

> Momenta Pharmaceuticals paid $4.5 million upfront and promised up to $51.5 million more to gain the rights to the Sialic Switch technology held by Virdante Pharmaceuticals. "Virdante's Sialic Switch technology represents an exciting approach to potentially regulate anti-inflammatory activity of proteins," said Ganesh Venkataraman, the CSO at Momenta. "Sialylation complements our existing technology platform and we look forward to advancing this technology in development programs, including biobetters and novel products." Release

> Japan's Takeda plans to launch a new global vaccines division next year. News

> Regeneron shares slipped this morning after the biotech said that new data failed to demonstrate that its newly approved drug Eylea worked better than Roche's Lucentis after two years of treatment. Story

> Watertown, MA- based EnVivo Pharmaceuticals says that it has presented positive Phase IIb data on an experimental schizophrenia drug. Release

 @FiercePharma: Sanofi abandons authorized Lovenox generic, now that Amphastar's copy isn't a threat to brand sales--BloombergMore | Follow @FiercePharma

> Who's on first for Icahn departee Alex Denner? Item

> Pain-drug market to stagnate on generic erosion, report says. Story

> Eylea data blurs dosing advantage over Lucentis. Article

> Abbott CEO: Pharma unit not for sale. Report

Biotech IT News

> Microsoft co-founder Allen urges open science to speed breakthroughs. Story

> Startup Spiral Genetics takes shot at bioinformatics. Article

> AstraZeneca taps IT outsourcing firm Cognizant. News

> Singapore group touts new genome assembly method. Report

> NYT: Data bottleneck stymies progress in genomics. Report

Medical Device News

Integra opens Shanghai office. News

> Qualcomm unit to provide wireless solutions for devices. More

> Moog taps Scannell as CEO. Item

And Finally... Investigators at the University of Missouri have shed new light on the way adult stem cells are attracted to the site of a muscle injury to help repair the damage. Their work could contribute to the development of new approaches to treating muscular dystrophy. Report

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.